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Highlights 
The transcription factor Myb is an emerging drug target for leukemia therapy. 
Initial work has identified several Myb-inhibitory compounds providing proof-of-principle that 
targeting of Myb is feasible. 
Small-molecule suppression of Myb activity preferentially inhibits proliferation of leukemic 
versus normal hematopoietic cells. 
 
Abstract 
The transcription factor Myb is a key regulator of hematopoietic cell proliferation, 
differentiation and survival and has been implicated in the development of leukemia and 
several other human cancers. Pharmacological inhibition of Myb is therefore emerging as a 
potential therapeutic strategy. Recently, the first low molecular weight compounds that show 
Myb inhibitory activity have been identified. Characterization of these compounds suggests 
disruption of the protein-protein-interaction of Myb and the co-activator p300 as a suitable 
strategy to inhibit Myb. 
 
The transcription factor Myb 
Myb was initially discovered as the protein encoded by the cellular counterpart (c-myb) of the 
retroviral oncogene (v-myb) of the avian myeloblastosis virus. Together with two related 
proteins, A-Myb (or Mybl1) and B-Myb (or Mybl2), Myb forms a family of transcription factors 
in humans and other vertebrates, whose members share a highly conserved DNA-binding 
domain but have distinct functions and expression patterns. Myb is highly expressed in 
immature cells of all hematopoietic lineages and plays a key role as a regulator of 
hematopoietic cell proliferation, differentiation and survival [1,2]. Myb-null mice die during 
embryonic development and show multiple defects of almost all hematopoietic lineages, 
demonstrating that Myb is essential for the development of the hematopoietic system [3]. 
Studies with conditional Myb knock-out mice have identified distinct steps during the 
differentiation of the different lineages that are dependent on Myb expression [4,5,6,7]. Myb 
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is also expressed, although at lower levels, in certain epithelial cell types, such as the stem 
cells of the intestinal epithelium [8]. By contrast, A-Myb is mainly expressed in the male germ 
line, in the female breast epithelium and in B-cells whereas B-Myb is ubiquitously expressed 
in proliferating cells and functions as a cell cycle-dependent transcription factor [2,9].  
The Myb protein structure consists of an N-terminal DNA binding domain that recognizes the 
consensus nucleotide motif PyAACT/GG, a transactivation domain located in the center of the 
protein and a C-terminal negative-regulatory domain. A variety of proteins interacting with 
Myb have been identified and implicated in regulating its activity (Fig.1). Of these proteins the 
co-activator p300 plays a pivotal role as a Myb interaction partner. p300 is recruited to Myb 
via its so-called KIX domain that binds to a LXXLL amino acid motif located in the 
transactivation domain of Myb [10]. Importantly, mouse strains that are defective in the Myb-
KIX interaction due to mutations of the LXXLL-motif or the KIX domain show multiple 
hematopoietic defects [11,12,13], pinpointing an essential role of p300 as a cooperation 
partner of Myb in the hematopoietic system. Structural analyses of a complex of the KIX-
domain and a short peptide containing the LXXLL-motif of Myb have revealed that this motif 
and the adjoining amino acids form an α-helix that binds to a hydrophobic groove on the 
surface of the KIX domain [10].   
 
Role of Myb in human leukemia 
The initial discovery of v-myb as the oncogene responsible for the ability of AMV to cause 
myeloid leukemia in chickens suggested that Myb might also play a role in human leukemia. 
Although several studies showed that Myb is highly expressed in most human acute myeloid 
and lymphoid leukemias [14], it remained open whether high Myb expression plays a causal 
role in the development of the leukemia or is just a consequence of the immature phenotype 
of the leukemic cells. However, with the emergence of sophisticated and sensitive methods 
to detect chromosomal alterations, recurrent translocations and duplications of the MYB 
locus were described in T-cell acute lymphoid leukemias [15,16,17], providing clear evidence 
for a role of MYB in the etiology of this type of leukemia. Subsequent work reported genomic 
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rearrangements of Myb in acute myelomonocytic and basophilic leukemia [18,19,20]. 
Furthermore, mutations generating de novo Myb binding sites upstream of the TAL1 
oncogene were recently detected in a significant fraction of T-ALL of children [21]. These 
changes were shown to create „super-enhancers“ that lead to over-expression of Tal1 which, 
in turn, causes the leukemia. Together, these findings have provided strong evidence that 
Myb plays a causal role in the development of certain leukemias. However, it has now been 
recognized that Myb plays also an essential role as a „maintenance factor“ in leukemias 
caused by genetic lesions of other genes, such as the recurrent chromosomal translocations 
that lead to the expression of various fusion proteins, including AML-ETO, CBFb-SMMHC, 
PML-RARa, MLL-AF9, MLL-ENL and others. Acute myeloid leukemias caused by these 
translocations show high levels of Myb expression that are essential for the maintenance of 
the leukemic cells. This has initially been observed in studies with Myb antisense 
oligonucleotides [22,23] and confirmed by more recent studies [24,25,26,27]. The concept 
that has emerged from this work is that the survival and proliferation of the leukemic cells 
requires high levels of Myb acting downstream of the oncogenic driver mutations. 
Importantly, the leukemic cells require - or are „addicted“ to - higher levels of Myb expression 
than normal hematopoietic progenitor cells. This phenomenon provides a rationale for a 
therapeutic approach based of Myb inhibition because it predicts that leukemic cells will be 
more sensitive to inhibition of Myb than normal hematopoietic progenitor cells. This idea is 
supported by recent studies of a mouse model of acute myeloid leukemia (AML), which 
showed that shRNA-mediated down-regulation of Myb resulted in remission of the leukemia 
without inhibiting normal hematopoiesis [26]. 
Myb has also been implicated in the development of non-hematopoietic tumors, such as 
breast and colon cancer [1], adenoid cystic carcinoma, a rare and currently intractable tumor 
which harbors translocations of the MYB and NFIB genes in a large proportion of cases [28], 
and diffuse low-grade pediatric gliomas [29]. Myb is therefore now regarded as a relevant 
target whose inhibition might open up novel strategies for the treatment of leukemia and 
other types of cancer.  
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Targeting Myb by small molecule inhibitors 
The idea that Myb may be a relevant therapeutic target has prompted us to search for low 
molecular weight compounds as potential Myb inhibitors. We have established a cell-based 
inhibitor screening system that employs a myelomonocytic chicken cell line carrying an 
inducible Myb expression system and a GFP-based reporter gene, which is driven by the 
promoter and enhancer of the highly Myb-inducible chicken mim-1 gene. Hence, the 
fluorescence of these cells is a direct measure of Myb activity. We initially used the cells to 
screen a collection of so-called sesquiterpene lactones (STLs) for Myb-inhibitory activity 
[30,31]. STLs are a large class of plant-derived natural compounds that have various 
biological activities. Surprisingly, already the first compound tested, Mexicanin-I, inhibited 
Myb activity in our reporter system at a low micromolar concentration. Further analysis 
showed that Mexicanin-I was able to inhibit the expression of bona fide Myb target genes 
and to suppress the proliferation of leukemia cell lines and of primary leukemic cells from 
several AML patients [30]. Although this study did not reveal how Mexicanin-I exerts its 
inhibitory effect, it showed for the first time that Myb activity can be inhibited by a low 
molecular weight compound. This finding was corroborated by the observation that Naphthol 
AS-E phosphate, a compound that was previously shown to bind to the KIX domain of p300 
and to inhibit its interaction with the transcription factor CREB [32], also inhibits Myb activity 
[33]. Consistent with its effect on the KIX-CREB interaction it was shown that Naphthol AS-E 
phosphate disrupts the interaction between Myb and the KIX domain. This demonstrated that 
disruption of the Myb/KIX protein-protein-interaction with a drug-like small molecule is 
feasible. Subsequently, we have identified additional compounds that target the cooperation 
of Myb and p300. We showed that Celastrol, a triterpenoid isolated from roots of 
Tripterygium wilfordii (Thunder God Vine), potently inhibits Myb activity (EC50 approx. 1 µM) 
by blocking the Myb-p300 interaction [34]. Molecular docking studies suggest that Celastrol 
is able to bind to the hydrophobic groove on the surface of the KIX domain that is occupied 
by the α-helical LXXLL-motif in the Myb-KIX complex, suggesting that Celastrol competes 
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with Myb for binding to the KIX domain. Further work showed that Celastrol down-regulates 
the expression of authentic Myb target genes in HL60 cells and induces differentiation and 
apoptosis, as expected if Myb activity is inhibited. Importantly, expression of an activated 
version of Myb in HL60 cells rescued the effects of Celastrol on differentiation and apoptosis, 
indicating that these effects were indeed mediated by inhibition of Myb. Celastrol also 
inhibited the proliferation of primary AML cells derived form a mouse model of AML and from 
AML patients. Importantly, the proliferation normal murine and human early hematopoietic 
progenitor cells was not affected under the same conditions, consistent with the notion that 
AML cells require higher levels of Myb activity than their normal counterparts and, hence, are 
more vulnerable to inhibition of Myb than the normal cells. Finally, it was shown that Celastrol 
significantly prolonged the survival of mice in an in vivo model of an aggressive AML [34]. 
Overall, this work suggested that small molecule inhibition of Myb might have therapeutic 
potential for the treatment of AML. 
Compounds binding to p300 are likely to have additional inhibitory activities because p300 is 
a co-activator of many transcription factors. We were therefore particularly interested in 
identifying compounds that act directly on Myb rather than on p300. Recently, we have 
shown that 5-hydroxy-2-methyl-1,4-naphthoquinone (also known as Plumbagin) and several 
related naphthoquinones bind directly to the transactivation domain of Myb and inhibit Myb 
activity [35]. Like Celastrol, Plumbagin induced the differentiation of HL60 cells and inhibited 
the proliferation of primary AML cells while the proliferation of normal progenitor cells was not 
affected. Naphthoquinones are well known for their ability to induce reactive oxygen species, 
however, this appeared not to be involved in the inhibition of Myb activity. Rather, Plumbagin 
appeared to disrupt the cooperation of Myb and p300. The 3-dimensional structure of the 
Myb transactivation domain is currently not known, nevertheless these findings suggest that 
this part of Myb displays a “binding pocket” that is amenable to binding by small molecules. 
Although Plumbagin is already quite active (EC50 approx. 0.5 µM) its rather simple chemical 
structure suggests that chemical approaches could be used to develop it further to more 
active compounds or to compounds that will minimize off-target effects. It will also be very 
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interesting to screen for further compounds that bind to the Myb transactivation domain, to 
eventually identify lead structures that can be developed into specific Myb inhibitors. 
Furthermore, in vivo leukemia models will be important tools to validate the targets being 
affected by the candidate drugs and to assess their therapeutic efficacy. 
 
Summary 
Myb is now regarded as a promising therapeutic target whose inhibition might open-up new 
strategies for the treatment of leukemia and of other tumors driven by deregulated Myb. 
Although the development of specific inhibitors for Myb is still in its infancy, initial attempts to 
find inhibitory compounds have successfully demonstrated that small molecule inhibition of 
Myb is feasible and may have potential for the therapy of AML. These studies have 
pinpointed disruption of the Myb/p300 protein-protein-interaction as suitable strategy to 
inhibit Myb activity. Thus, the stage is now ready for more sophisticated and extensive 
approaches to search for highly active small-molecule Myb inhibitors.  
 
Acknowledgments 
The authors’ work on Myb inhibitors was supported by the Deutsche Krebshilfe, the 
Deutsche Jose Carreras Leukämie-Stiftung e.V., the Adenoid Cystic Carcinoma Research 
Foundation, the Wellcome Trust and Bloodwise. 
 
Conflict of interest disclosure 
The authors declare no conflict on interest. 
 
References 
1. Ramsay, R.G. and Gonda, T.J. Myb function in normal and cancer cells. Nat Rev Cancer.  
2008; 8: 523-534 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 8 
2. Zhou, Y. and Ness, S.A. Myb proteins: Angels and demons in normal and transformed 
cells. Front Biosci. 2011; 16: 1109-1131 
3. Mucenski, M.L., McLain, K., Kier, A.B. et al. A functional c-myb gene is required for normal 
murine fetal hepatic hematopoiesis. Cell, 1991; 65: 677-689 
4. Bender, T.P., Kremer, C.S., Kraus, M., Buch, T. and Rajewsky, K. Critical functions for 
Myb at three checkpoints during thymocyte development. Nat Immunol. 2004; 5: 721-729 
5. Emambokus, N., Vegiopoulos, A., Harman, B., Jenkinson, E., Anderson, G. and Frampton, 
J. Progression through key stages of haemopoiesis is dependent on distinct threshold 
levels of Myb. EMBO J. 2003; 22: 4478-4488 
6. Thomas, M.D., Kremer, C.S., Ravichandran, K.S., Rajewsky, K. and Bender T.P. Myb is 
critical for B cell development and maintenance of follicular B cells. Immunity. 2005; 23: 
275-286 
7. Sakamoto, H., Dai, G., Tsujino, K. et al. Proper levels of c-Myb are discretely defined at 
distinct steps of hematopoietic cell development. Blood. 2006; 108: 896-903 
8. Malaterre, J., Carpinelli, M., Ernst, M. et al. Myb is required for progenitor cell homeostasis 
in colonic crypts. Proc Natl Acad Sci USA. 2007; 104: 3829-3834 
9. Sala, A. B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and 
cancer. Eur J Cancer. 2005; 41: 2479-2484  
10. Zor, T., De Guzman, R.N., Dyson, H.J. and Wright, P.E. Solution structure of the KIX 
domain of CBP bound to the transactivation domain of c-Myb. J Mol Biol. 2004; 337: 521-
534 
11. Kasper, L.H., Boussouar, F., Ney, P.A. et al. A transcription-factor-binding surface of 
coactivator p300 is required for haematopoiesis. Nature. 2002; 419: 738-743 
12. Sandberg, M.L., Sutton, S.E., Pletcher, M.T. et al. Myb and p300 regulate hematopoietic 
stem cell proliferation and differentiation. Dev Cell. 2005; 8: 153-166 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 9 
13. Papathanasiou, P., Tunningley, R., Pattabiraman, D.R. el al. A recessive screen for 
genes regulating hematopoietic stem cells. Blood. 2010; 116: 5849-5858 
14. Westin, E.H., Gallo, R.C., Arya, S.K. et al. Differential expression of the amv gene in 
human hematopoietic cells. Proc Natl Acad Sci USA. 1982; 79: 2194-2198  
15. Lahortiga, I., De Keersmaecker, K., Van Vlierberghe, P. et al. Duplication of the MYB 
oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007; 39: 593-595 
16. Clappier, E., Cuccuini, W., Kalota, A. et al. The MYB locus is involved in chromosomal 
translocation and genomic duplications in human T-cell acute leukemia (T-ALL), the 
translocation defining a new T-ALL subtype in very young children. Blood. 2007; 110: 
1251-1261  
17. O’Neil, J., Tchinda, J., Gutierrez, A. et al. Alu elements mediate MYB gene tandem 
duplication in human T-ALL. J Exp Med. 2007; 204: 3059–3066 
18. Murati, A., Gervais, C., Carbuccia, N. et al. Genome profiling of acute myelomonocytic 
leukemia: alteration of the MYB locus in MYST3-linked cases. Leukemia. 2009; 23: 85-94  
19. Belloni, E., Shing, D., Tapinassi, C. et al. In vivo expression of an aberrant MYB-GATA1 
fusion induces leukemia in the presence of GATA1 reduced levels. Leukemia. 2011; 25: 
733-736  
20. Quelen, C., Lippert, E., Struski, S. et al. Identification of a transforming MYB-GATA1 
fusion gene in acute basophilic leukemia: a new entity in male infants. Blood. 2011; 117: 
5719-5722 
21. Mansour, M.R., Abraham, B.J., Anders, L. et al. Oncogene regulation. An oncogenic 
super-enhancer formed through somatic mutation of a noncoding intergenic element. 
Science. 2014;346: 1373-1377 
22. Anfossi, G., Gewirtz, A.M. and Calabretta, B. An oligomer complementary to Myb-
encoded mRNA inhibits proliferation of human myeloid leukemia cell lines. Proc Natl 
Acad Sci USA. 1989; 86: 3379-3383 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 10
23. Calabretta, B., Sims, R.B., Valtieri, M. et al. Normal and leukemic hematopoietic cells 
manifest differential sensitivity to inhibitory effects of Myb antisense 
oligodeoxynucleotides: an in vitro study relevant to bone marrow purging. Proc Natl Acad 
Sci USA. 1991; 88: 2351-2355 
24. Hess, J.L., Bittner, C.B., Zeisig, D.T. et al. Myb is an essential downstream target for 
homeobox-mediated transformation of hematopoietic cells. Blood. 2006; 108: 297–304 
25. Somervaille, T.C., Matheny, C.J., Spencer, G.J. et al. Hierarchical maintenance of MLL 
myeloid leukemia stem cells employs a transcriptional program shared with embryonic 
rather than adult stem cells. Cell Stem Cell. 2009; 4: 129-140  
26. Zuber, J., Rappaport, A.R., Luo, W. et al. An integrated approach to dissecting oncogene 
addiction implicates a Myb-coordinated self-renewal program as essential for leukemia 
maintenance. Genes Dev. 2011; 25: 1628-1640 
27. Huang, Y., Sitwala, K., Bronstein, J. et al. Identification and characterization of Hoxa9 
binding sites in hematopoietic cells. Blood. 2012;119: 388-398 
28. Persson, M., Andrén, Y., Mark, J., Horlings ,H.M., Persson, F. and Stenman, G. 
Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast 
and head and neck. Proc Natl Acad Sci USA. 2009; 106: 18740-18744   
29. Zhang, J., Wu, G., Miller, C.P. et al. Whole-genome sequencing identifies genetic 
alterations in pediatric low-grade gliomas. Nat Genet. 2013; 45: 602-612 
30. Bujnicki, T., Wilczek, C., Schomburg, C. et al. Inhibition of Myb-dependent gene 
expression by the sesquiterpene lactone mexicanin-I. Leukemia. 2012; 26: 615-622  
31. Schomburg, C., Schuehly, W., Da Costa, F.B., Klempnauer, K.-H. and Schmidt, T.J. 
Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: 
structure-activity relationships. Eur J Med Chem. 2013; 63: 313-320 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 11
32. Best, J.L., Amezcua, C.A., Mayr, B. et al. Identification of small-molecule antagonists that 
inhibit an activator: coactivator interaction. Proc Natl Acad Sci USA. 2004; 101: 17622–
17627 
33. Uttarkar, S., Dukare, S., Bopp, B., Goblirsch, M., Jose, J. and Klempnauer, K.-H. 
Naphthol AS-E phosphate inhibits the activity of the transcription factor Myb by blocking 
the interaction with the KIX domain of the coactivator p300. Mol Cancer Ther. 2015; 14: 
1276-1285 
34. Uttarkar, S., Dassé, E., Coulibaly, A. et al. Targeting acute myeloid leukemia with a small 
molecule inhibitor of the Myb/p300 interaction. Blood. 2016;127: 1173-1182 
35. Uttarkar, S., Piontek, T., Dukare, S. et al. Small-molecule disruption of the Myb/p300 
cooperation targets acute myeloid leukemia cells. Mol Cancer Ther. 2016; 15: 2905-2915 
 
 
Figure legends 
 
Figure 1. Myb interaction partners. The functional domains and several known interaction 
partners of Myb are shown schematically. LXXLL refers to an amino acid motif in the 
transactivation domain that mediates the interaction with p300. 
  
Figure 2. Proposed inhibitory mechanisms of Celastrol and Plumbagin. The formation of 
a complex through the LXXLL motif of Myb and the KIX domain of Myb is shown 
schematically. Celastrol and Plumbagin are shown interfering with the Myb/p300 interaction 
by primarily targeting the KIX domain or the Myb transactivation domain.  
p300 
FLASH 
p100 
Menin 
Mybbp1a 
Tif-1b 
PRMT4 c-Ski 
N-CoR 
Mi-2α	
activation DNA-binding regulation 
Myb 
LXXLL 
NLK	
Hipk1 
Figure1 
p300   
Kix 
Myb	
Plumbagin 
O
OOH
CH3
Celastrol 
Figure 2 
